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debris capture rate of 93% in any or both ﬁlters. Finding debris in the
proximal ﬁlter was more common (100%) than in the distal ﬁlter (86%).
Acute thrombus was the most common type of debris, captured in 64%
of theﬁlters. In 28%, valve and arterial wall tissue and calciﬁcationwere
also found, with the percentage of debris higher in the proximal ﬁlter.
Organized thrombus was found in 7%; foreign material was also found
in 7% of all cases, but only in the distal ﬁlter.
CONCLUSIONS Histopathological analyses showed high overall debris
capture rates, with higher prevalence of thrombus over valve and arterial
wall tissue, calciﬁcation and foreign material. Procedural stroke rate was
0%. Further investigation (especially histopathological) is needed to
investigate the characterization of the debris and to differentiate between
valve-in-valve procedures in the aortic and mitral position.
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BACKGROUND Transapical access for transcatheter aortic valve im-
plantation (TA-TAVI) has become a routine procedure for patients at
high surgical risk and is a valid alternative to transfemoral TAVI.
Transapical access has seen little standardization of technique due to
the absence of automated preclosure and carries a risk for bleeding
complications. Here we describe the use of a novel device designed to
facilitate safe and reliable, automated transmyocardial access and
closure during structural heart interventions such as TA-TAVI.
METHODS A total of 34 patients in 1 Dutch and 4 German centers
underwent transapical TAVI through mini-thoracotomies using the
Permaseal closure device (STASIS trial). All patients received Edwards
Sapien 3 or Sapien XT valves. The closure device consists of 8 poly-
propylene anchors connected by a braided polyester pre-tied suture
allowing for the passage of sheaths up to 30 Fr. Anchors are me-
chanically deployed into the myocardial tissue near the anatomical
apex using an over the wire system. After removal of the TAVI sheath,
hemostasis is achieved by advancement of the pre-tied suture, and
approximation of the anchors without the need for fast pacing. All
patients were prospectively followed for 30 and 90 days.
RESULTS The Permaseal apical closure device was successfully
deployed in all patients. Hemostasis was achieved with no or only one
additional pledgeted suture after sheath removal and anchor approxi-
mation by closing of the pre-tied suture in 94.1% of patients. In 2 pa-
tients additional sutures were applied to resolve ongoing bleeding from
the apical access site. Two patients (one roll-in patient and one protocol
deviation) were excluded from the efﬁcacy analysis. Three patients
(8.8%) required transfusion of more than 2 units either peri-proce-
durally or prior to discharge. Mean operation time was 86  22.5 min
and mean length of stay in the hospital was 9.53.2 days. Pulsatile
bleeding was not reported and re-intervention was not required for any
patient following the surgical procedure, at hospital discharge, 30-day
follow-up or 90-day follow-up. No patients died during 30 day follow-
up, however one patient died on day 37 from complications related to
hip replacement surgery. No patients suffered strokes or myocardial
infarctions during the 90 day follow-up period.
CONCLUSIONS The Permaseal device allows for minimally invasive
reproducible access and closure of the left ventricular apex for TA
TAVI. The device complies with the beating heart and shows no
interference with wall motion while leaving only little foreign mate-
rial behind. This access and closure approach may help to reduce OR
time, abate blood loss, and simplify transapical access for TAVI.
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BACKGROUND POL-TAVI is an on-going all-comer registry enrolling
all TAVI procedures in Poland since 2009. Within the registry baseline
clinical, imaging and procedural data as well as in-hospital, early (30
days) and long-term (6 and 12 months) outcomes are prospectively
registered and reported yearly. Aim of the study was to evaluate the
outcomes of TAVI patients presenting with chronic anemia.
METHODS The registry enrolled 381 patients treated in 2013 (43,6%
males, mean age of 78,757,4 years, logistic EuroScore 20,214,5, STS
8,528,3). Anemia was diagnosed based on WHO deﬁnition (Hb <13 g/
dL for men and <12 g/dL for women).
RESULTS There were 184 (47,5%) patients with anemia. In comparison to
patients without anemia they were signiﬁcantly older (79,77,2 vs.
77,97,4, p<0.03). Both groups had comparable Log EuroScore (21,114,5
vs. 19,514,5, p¼0.16), NYHA and CCS class. Patients with anemia have
moreoften creatinine level> 200umol/l (10,87 vs. 3.6%, p<0.01) and lower
GFR (50,319,9 vs. 59,419,2mL/min, p<0,001) on admission. The groups
didnotdiffer in the frequencyof chronicdialysisprior toAVaswell as acute
kidney injury post TAVI (14,67% vs. 9,33%, p¼0.11). Patients with anemia
requiredmore blood transfusion post TAVI (49,18% vs. 27,2%, p<0.001). A
trend to higher mortality in a group of patients with anemia on admission
could be observed at 1 month (12,20 vs. 8,9%, p¼0,36), 6 months (21,97 vs.
13,9%, p¼0,11) which became signiﬁcant at 12 months (34,31 vs. 17,43%,
P<0,01). In logistic regression analysis presence of anemia was an inde-
pendent predictor of death at 1 year [OR 95%CI 2,47 (1,32;4,77), p¼0,0048]
similarly to drop in Hb level during hospitalization [OR 95% CI 0,82
(0,67;0,99), p¼0.039 for decrease of by 1 g/dL]. The need of transfusion
increased the risk of death 3,2 times (OR 95% CI 3,23 (1,70;6,32), p<0,002).
CONCLUSIONS Chronic anemia is present in almost 48% of patients un-
dergoing TAVI and associated with 2,5-fold higher mortality in 12 months
follow-up. Signiﬁcant drop in hemoglobin levels and need of blood trans-
fusion also signiﬁcantly increased the short and long term mortality.
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BACKGROUND An inverse association between bodymass index (BMI)
andmortality in patients after Transcatheter Aortic Valve Replacement
(TAVR) has been reported. This ’obesity paradox’ is controversial,
however, because not all TAVR series have demonstrated such a rela-
tionship betweenBMI andmortality. Body surface area (BSA)might be a
more suitable marker to identify patients at risk for mortality following
TAVR, but little is currently known about its prognostic value.
METHODS This prospective, observational study consisted of 917
consecutive patients undergoing TAVR at our center from 2011-
2014. The association between BSA and mortality (at 30-days and
1-year) was assessed using restricted cubic spline functions in a
propensity-adjusted (by Society of Thoracic Surgeons’ risk factors)
logistic and Cox proportional model, respectively.
RESULTS Mean follow-up time was 141 days. Throughout the study
period, 152 (16.5%) patients died; 72 (7.9%) patients died within 30
